Combination of EGFR Inhibitor Lapatinib and MET Inhibitor Foretinib Inhibits Migration of Triple Negative Breast Cancer Cell Lines

Triple-negative breast cancer (TNBC) is the most challenging subtype to treat due to the lack of estrogen receptor, progesterone receptor, and HER2 expression, which excludes the usage of directed targeted therapy against them. Promising therapeutic targets are the hepatocyte growth factor receptor...

Descripción completa

Detalles Bibliográficos
Autores principales: Simiczyjew, Aleksandra, Dratkiewicz, Ewelina, Van Troys, Marleen, Ampe, Christophe, Styczeń, Ilona, Nowak, Dorota
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6162814/
https://www.ncbi.nlm.nih.gov/pubmed/30227653
http://dx.doi.org/10.3390/cancers10090335

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6162814/
https://www.ncbi.nlm.nih.gov/pubmed/30227653
http://dx.doi.org/10.3390/cancers10090335

Ejemplares similares